Lysosomal enzymes in preterm infants with bronchopulmonary dysplasia: a potential diagnostic marker

Clin Chim Acta. 1998 Nov;278(1):23-34. doi: 10.1016/s0009-8981(98)00129-6.


Some lysosomal glycohydrolases (N-acetyl-beta-D-glucosaminidase and their major isoenzymes, beta-D-glucuronidase, alpha-D-galactosidase, beta-D-galactosidase and alpha-D-glucosidase) were investigated in the plasma of 36 preterm infants with respiratory distress, 11 of whom developed bronchopulmonary dysplasia (BPD), in order to evaluate the role of the lysosomal apparatus in the disease. Enzyme activity was assayed fluorimetrically; the major N-acetyl-beta-D-glucosaminidase (NAG) isoenzymes were separated using a routine chromatofocusing procedure; the diagnostic efficiency was evaluated by Bayes theorem. The mean levels of almost all glycohydrolases considered were significantly higher in BPD than in non-BPD infants. Among NAG major isoenzymes, an increase was found only in form A. No variation was evident in the plasma levels of glycohydrolases during dexamethasone therapy. Data from a retrospective analysis performed in all preterms considered, show that alpha-D-galactosidase and beta-D-galactosidase differentiate a posteriori BPD and non-BPD subjects. These enzymes, after a priori verification of their diagnostic potential in preterm infants at risk of BPD development, could acquire an important predictive value.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood*
  • Bronchopulmonary Dysplasia / drug therapy
  • Bronchopulmonary Dysplasia / enzymology*
  • Dexamethasone / therapeutic use
  • Glycoside Hydrolases / blood*
  • Humans
  • Infant, Newborn
  • Infant, Premature / blood*
  • Lysosomes / enzymology*


  • Biomarkers
  • Dexamethasone
  • Glycoside Hydrolases